Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

Running, not enrolling · Not applicable

Conditions studied: Prostate Cancer

In brief

This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.

Key facts

Study ID
NCT05345444
Run by
Weill Medical College of Cornell University
People needed
48
Starts
2022-05-26
Expected to finish
2027-08-01
Last updated by the study team
2026-07-29

Who can join

Age: 18 and older, up to 99. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.